INS and Hypoglycemia: After adding basal insulin to CVII therapy, the daily insulin dose decreased, and glycemic control further improved with an acceptable hypoglycemia risk, indicating that timely and adequate basal insulin replacement was important during the postoperative parenteral period after TP.